[1] Piske M, Budd MA, Qiu AQ, et al. Neurodevelopmental outcomes and in-utero antiretroviral exposure in HIV-exposed uninfected children. AIDS, 2018; 32, 2583−92.
[2] Joint United Nations Programme on HIV/AIDS (UNAIDS). Global AIDS update. Ending AIDS: progress towards the 90-90-90 targets. Geneva: Joint United Nations Programme on HIV/AIDS (UNAIDS), July 2017. http://www.unaids.org/sites/default/files/media_asset/Global_AIDS_update_2017_en.pdf. [2019-6-12]
[3] Bokharaei-Salim F, Kalantari S, Gholamypour Z, et al. Investigation of the effects of a prevention of mother-to-child HIV transmission program among Iranian neonates. Arch Virol, 2018; 163, 1179−85. doi:  10.1007/s00705-017-3661-1
[4] Chen Fangfang, Qin Qianqian, Cai Chang, et al. Spatial-temporal distribution of newly detected HIV/AIDS cases among aged 15 years or older women in China, 2010-2016. Chin J Epidemiol, 2018; 39, 739−44. (In Chinese)
[5] Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med, 1994; 331, 1173−80. doi:  10.1056/NEJM199411033311801
[6] The Petra study team. Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial. Lancet, 2002; 359, 1178−86. doi:  10.1016/S0140-6736(02)08214-4
[7] Cooper ER, Charurat M, Mofenson L, et al. Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission. J Acquir Immune Defic Syndr, 2002; 29, 484−94. doi:  10.1097/00042560-200204150-00009
[8] Lallemant M, Jourdain G, Le Coeur S, et al. Single-dose perinatal nevirapine plus standard zidovudine to prevent mother-to-child transmission of HIV-1 in Thailand. N Engl J Med, 2004; 351, 217−28. doi:  10.1056/NEJMoa033500
[9] Schouten EJ, Jahn A, Midiani D, et al. Prevention of mother-to-child transmission of HIV and the health-related Millennium Development Goals: time for a public health approach. Lancet, 2011; 378, 282−84. doi:  10.1016/S0140-6736(10)62303-3
[10] World Health Organization. Antiretroviral drugs for treating pregnant women and preventing HIV infection in infants: recommendations for a public health approach (2010 version). Geneva: World Health Organization, November 2010. http://www.who.int/hiv/pub/mtct/guidelines/en/.[2019-6-12]
[11] World Health Organization. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach, June 2013. http://apps.who.int/iris/bitstream/10665/85321/1/9789241505727_eng.pdf. [2019-6-12]
[12] World Health Organization. Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Recommendations for a public health approach-2nd edition, December 2016. http://www.who.int/hiv/pub/arv/arv-2016/en/. [2019-6-12].
[13] Bailey H, Zash R, Rasi V, et al. HIV treatment in pregnancy. The Lancet HIV, 2018; 5, e457−e67. doi:  10.1016/S2352-3018(18)30059-6
[14] Malaba TR, Phillips T, Le Roux S, et al. Antiretroviral therapy use during pregnancy and adverse birth outcomes in South African women. Int J Epidemiol, 2017; 46, 1678−89. doi:  10.1093/ije/dyx136
[15] Luzuriaga K, Mofenson LM. Challenges in the Elimination of Pediatric HIV-1 Infection. N Engl J Med, 2016; 374, 761−70. doi:  10.1056/NEJMra1505256
[16] Wedi CO, Kirtley S, Hopewell S, et al. Perinatal outcomes associated with maternal HIV infection: a systematic review and meta-analysis. The Lancet HIV, 2016; 3, e33−48. doi:  10.1016/S2352-3018(15)00207-6
[17] Favarato G, Townsend CL, Bailey H, et al. Protease inhibitors and preterm delivery: another piece in the puzzle. AIDS, 2018; 32, 243−52.
[18] Chetty T, Thorne C, Coutsoudis A. Preterm delivery and small-for-gestation outcomes in HIV-infected pregnant women on antiretroviral therapy in rural South Africa: Results from a cohort study, 2010-2015. PloS One, 2018; 13, e019280−21.
[19] Zash R, Souda S, Chen JY, et al. Reassuring Birth Outcomes With Tenofovir/Emtricitabine/Efavirenz Used for Prevention of Mother-to-Child Transmission of HIV in Botswana. J Acquir Immune Defic Syndr, 2016; 71, 428−36. doi:  10.1097/QAI.0000000000000847
[20] Shapiro R, Dryden-Peterson S, Powis K, et al. Hidden in plain sight: HIV, antiretrovirals, and stillbirths. Lancet, 2016; 387, 1994−5. doi:  10.1016/S0140-6736(16)30459-7
[21] Saleska JL, Turner AN, Maierhofer C, et al. Use of antiretroviral therapy during pregnancy and adverse birth outcomes among women living with HIV-1 in low- and middle-income countries: a systematic review. J Acquir Immune Defic Syndr, 2018; 79, 1−9. doi:  10.1097/QAI.0000000000001770
[22] Li N, Sando MM, Spiegelman D, et al. Antiretroviral Therapy in Relation to Birth Outcomes among HIV-infected Women: A Cohort Study. J Infect Dis, 2016; 213, 1057−64. doi:  10.1093/infdis/jiv389
[23] Masaba R, Borkowf CB, Girde S, et al. Adverse fetal and infant outcomes among HIV-infected women who received either NNRTI- or PI-based ART for PMTCT. AIDS, 2018; 32, 1625−32. doi:  10.1097/QAD.0000000000001816
[24] Heffron R, Mugo N, Hong T, et al. Pregnancy outcomes and infant growth among babies with in utero exposure to tenofovir-based pre-exposure prophylaxis for HIV prevention. AIDS, 2018; 32, 1707−13. doi:  10.1097/QAD.0000000000001867
[25] Uthman OA, Nachega JB, Anderson J, et al. Timing of initiation of antiretroviral therapy and adverse pregnancy outcomes: a systematic review and meta-analysis. The Lancet HIV, 2017; 4, e21−e30. doi:  10.1016/S2352-3018(16)30195-3
[26] Villar J, Cheikh Ismail L, Victora CG, et al. International standards for newborn weight, length, and head circumference by gestational age and sex: the Newborn Cross-Sectional Study of the INTERGROWTH-21st Project. Lancet, 2014; 384, 857−68. doi:  10.1016/S0140-6736(14)60932-6
[27] Fenton TR, Sauve RS. Using the LMS method to calculate Z-scores for the Fenton preterm infant growth chart. Eur J Clin Nutr, 2007; 61, 1380−5. doi:  10.1038/sj.ejcn.1602667
[28] World Health Organization. WHO child growth standards: length/height-for-age, weight-for-age, weight-for-length, weight-for-height and body mass index-for-age: methods and development. WHO Multicentre Growth Reference Study Group 2006, http://www.who.int/childgrowth/standards/technical_report/en/. [2017-9-12].
[29] Powis KM, Smeaton L, Hughes MD, et al. In-utero triple antiretroviral exposure associated with decreased growth among HIV-exposed uninfected infants in Botswana. AIDS, 2016; 30, 211−20. doi:  10.1097/QAD.0000000000000895
[30] Chen JY, Ribaudo HJ, Souda S, et al. Highly active antiretroviral therapy and adverse birth outcomes among HIV-infected women in Botswana. J Infect Dis, 2012; 206, 1695−705. doi:  10.1093/infdis/jis553
[31] Dadabhai S, Gadama L, Chamanga R, et al. Pregnancy Outcomes in the Era of Universal Antiretroviral Treatment in Sub-Saharan Africa (POISE Study). J Acquir Immune Defic Syndr, 2019; 80, 7−14. doi:  10.1097/QAI.0000000000001875
[32] Sibiude J, Warszawski J, Tubiana R, et al. Premature delivery in HIV-infected women starting protease inhibitor therapy during pregnancy: role of the ritonavir boost? Clin Infect Dis, 2012; 54, 1348−60. doi:  10.1093/cid/cis198
[33] Thorne C, Aebi-Popp K. Beyond prevention of mother-to-child HIV transmission. The lancet HIV, 2016; 3, e5−6. doi:  10.1016/S2352-3018(15)00243-X
[34] Aaron E, Bonacquisti A, Mathew L, et al. Small-for-gestational-age births in pregnant women with HIV, due to severity of HIV disease, not antiretroviral therapy. Infectious diseases in obstetrics and gynecology, 2012; 2012, 135030.
[35] Snijdewind IJM, Smit C, Godfried MH, et al. Preconception use of cART by HIV-positive pregnant women increases the risk of infants being born small for gestational age. PloS one, 2018; 13, e0191389. doi:  10.1371/journal.pone.0191389
[36] Phiri K, Williams PL, Dugan KB, et al. Antiretroviral Therapy Use During Pregnancy and the Risk of Small for Gestational Age Birth in a Medicaid Population. Pediatr Infect Dis J, 2015; 34, e169−75. doi:  10.1097/INF.0000000000000712
[37] Briand N, Mandelbrot L, Le Chenadec J, et al. No relation between in-utero exposure to HAART and intrauterine growth retardation. AIDS, 2009; 23, 1235−43. doi:  10.1097/QAD.0b013e32832be0df
[38] Jao J, Abrams EJ. Metabolic complications of in utero maternal HIV and antiretroviral exposure in HIV-exposed infants. The Pediatr Infect Dis J, 2014; 33, 734−40. doi:  10.1097/INF.0000000000000224
[39] HE Yan, LUO Yan, DING Yi-ling, et al. Effect of highly active anti-retroviral therapy on prevention of mother to child transmission of HIV and on infant growth and development. Chin J Pre Med, 2011; 45, 912−15. (In Chinese)
[40] Rosala-Hallas A, Bartlett JW, Filteau S. Growth of HIV-exposed uninfected, compared with HIV-unexposed, Zambian children: a longitudinal analysis from infancy to school age. BMC Pediat, 2017; 17, 80. doi:  10.1186/s12887-017-0828-6
[41] Omoni AO, Ntozini R, Evans C, et al. Child Growth According to Maternal and Child HIV Status in Zimbabwe. Pediatr Infect Dis J, 2017; 36, 869−76. doi:  10.1097/INF.0000000000001574
[42] S MlR, Jao J, Brittain K, et al. Tenofovir exposure in utero and linear growth in HIV-exposed, uninfected infants. AIDS, 2017; 31, 97−104. doi:  10.1097/QAD.0000000000001302
[43] Watts DH, Williams PL, Kacanek D, et al. Combination antiretroviral use and preterm birth. J Infect Dis, 2013; 207, 612−21. doi:  10.1093/infdis/jis728
[44] Marazzi MC, Palombi L, Nielsen-Saines K, et al. Extended antenatal use of triple antiretroviral therapy for prevention of mother-to-child transmission of HIV-1 correlates with favorable pregnancy outcomes. AIDS, 2011; 25, 1611−8. doi:  10.1097/QAD.0b013e3283493ed0